Emmanuel Demont

Head of Medicinal Chemistry

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Emmanuel Demont is the Head of Medicinal Chemistry at Apollo Therapeutics, located in the United Kingdom. His research focuses on the discovery and optimization of bromodomain inhibitors, with recent publications highlighting novel inhibitors suitable for clinical progression and domain-selective targeting of BET proteins in cancer and immunological diseases. His work emphasizes structure-based design strategies for selective inhibition of TAF1 bromodomain and their therapeutic potential.

Articles (4)

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (1)

Natalie Theodoulou

University of Manchester

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Emmanuel Demont

Research Interests

Explore related searches

Contact this professor

About

Articles (4)

Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression

Optimization of Naphthyridones into Selective TATA-Binding Protein Associated Factor 1 (TAF1) Bromodomain Inhibitors

Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype

Domain-selective targeting of BET proteins in cancer and immunological diseases

Collaborators (1)

Natalie Theodoulou

Make your next move.